VX-264
Cell therapy
Evidence outlook · program status
Discontinued (2025-03-28), after a negative readout
On 28 March 2025 Vertex announced results from the Phase 1/2 study of VX-264 (NCT05791201) and said the programme will not advance further in clinical development. Vertex later stated that the study did not meet its efficacy endpoint and took a $379.0 million impairment charge for VX-264. The registry record stays open for long-term follow-up only. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05791201 NCT05791201 · Type 1 Diabetes Registry: NCT05791201 | 1/2 | Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 up to 24 months); Part B: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT) (From Baseline and at Day 90) 2027-03-12 | Phase 1/2 did not meet its efficacy endpoint; Vertex discontinued the programme (2025-03-28). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other Pancreatic islet cell replacement drugs
Zimislecel. Compare all 2 Pancreatic islet cell replacement drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VX-264: this drug | Discontinued | Cell therapy | Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary | |
| Zimislecel | Phase 3(overall) | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Development was discontinued on 2025-03-28 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they are not pending readouts.
2027 (1)
March 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent